Assessment of Ophthalmological safety of skin care product
- Registration Number
- CTRI/2023/11/059530
- Lead Sponsor
- DPKA UNIVERSAL CONSUMER VENTURES PRIVATE LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)Indian Female subjects.
2)Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup)
3)Between 18 and 40 years of age.
4)Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….)
5)Subjects having normal eye conditions.
1 Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.
2 Having refused to give her assent by not signing the consent form.
3 Taking part in another study liable to interfere with this study.
4 Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months).
5 Having a progressive asthma (either under treatment or last fit in the last 2 years)
6 Being epileptic.
7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months).
8 Having cutaneous hypersensitivity.
9 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
10 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
11 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.
12 Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit.
13 Having applied a cosmetic product (included make-up) or skin care product on the studied areas the first day of the study (only face cleaned with water is accepted).
14 Refusing to follow the restrictions below during the study:
- Do not take part in any family planning activities leading to pregnancy and breastfeeding
- Do not take part in another study liable to interfere with this study
- Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
- Do not change cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit.
- During the study: Do not use other eye related and/ or eye make up than the tested products to the studied areas. (only test cleanser is accepted)
- The day of the measurements: No test product or any other eye make up must be used (only face cleaned with water is accepted)
15 Having applied products with an anti-wrinkle action particularly firming products (Retinoic acid, retinol, retinaldehyde, A.H.A….) in the 2 weeks preceding the start of the study.
16 Having undergone techniques with aesthetic aim (chemical peel, mechanical dermabrasion, laser, pulsed flash lamp …) in the previous 2 weeks.
17 Having undergone physical and/or chemical treatments of the spots (liquid nitrogen, dry ice, pulsed flash lamp, dermabrasion, chemical peel …) in the previous 1 month
18 Having had beauty treatment (e.g. scrub, self-tanning product …) on the studied areas in the previous week.
19 Having permanent make-up on the studied area.
20 Having ocular problems (stye, chalazion, conjunctivitis).
21 Having applied a cosmetic eye product (included eye make-up) or skin care product on the studied areas the day of the study (only face cleaned with water is accepted).
22 Refusing to follow the restrictions below during the study:
- Do not start, change or stop a hormonal treatment (hormonal contraception, cyproterone acetate …).
- Do not have beauty treatment (e.g. skin cleansing,
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ophthalmological safetyTimepoint: Baseline, 30 minutes, Day 1 and Day 3
- Secondary Outcome Measures
Name Time Method ilTimepoint: NA